menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

The Role of PARP Inhibitors in Metastatic Breast Cancer

ReachMD Healthcare Image
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Comments
  • Overview

    Two PARP inhibitors, olaparib and talazoparib, have been approved for the treatment of metastatic breast cancer (MBC) giving patients a promising new treatment option. Dive into the details of the trials for each therapy.

Facebook Comments

Recommended
Details
Comments
  • Overview

    Two PARP inhibitors, olaparib and talazoparib, have been approved for the treatment of metastatic breast cancer (MBC) giving patients a promising new treatment option. Dive into the details of the trials for each therapy.

Facebook Comments

Schedule12 Jul 2024